(Q38282790)

1 September 2017

1 reference

title

Perspectives of CD44 targeting therapies (English)

1 reference

1 September 2017

author

Véronique Orian-Rousseau

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

H Ponta

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

5 December 2014

1 reference

1 September 2017

published in

Archives of Toxicology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

3-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00204-014-1424-2

10 June 2020

exact match

0 references

cites work

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 is the principal cell surface receptor for hyaluronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Automated selection of anti-protein aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44: a validated target for improved delivery of cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

The tandemly repeated sequences of cartilage link protein contain the sites for interaction with hyaluronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

The miR-34 family in cancer and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44v6 dependence of premetastatic niche preparation by exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A five-amino-acid peptide blocks Met- and Ron-dependent cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Hyaluronan-CD44 interactions as potential targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44, a therapeutic target for metastasising tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 is required for two consecutive steps in HGF/c-Met signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Identification of hyaluronic acid binding sites in the extracellular domain of CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44: from adhesion molecules to signalling regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

MicroRNAs and cancer: short RNAs go a long way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Cancer stem cells: markers or biomarkers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Self-assembled pH-responsive hyaluronic acid-g-poly((L)-histidine) copolymer micelles for targeted intracellular delivery of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Deletion of the WNT Target and Cancer Stem Cell Marker CD44 in Apc(Min/+) Mice Attenuates Intestinal Tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1424-2

10.1007/S00204-014-1424-2

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25472903%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 June 2020

1033128567

0 references

Fatcat ID

release_2tmrxhspd5fghodyp7oyj4icgi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2tmrxhspd5fghodyp7oyj4icgi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference